Last Updated:
Searching
Create account to add to watchlist!

Chavant Capital Acquisition Corp. - CLAY

  • Commons

    $9.83

    -0.61%

    CLAY Vol: 216.0

  • Warrants

    $0.54

    +10.18%

    CLAYW Vol: 16.6K

  • Units

    $10.25

    +0.89%

    CLAYU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 98.3M
Average Volume: 54.5K
52W Range: $9.59 - $9.92
Weekly %: -0.30%
Monthly %: -0.30%
Inst Owners: 1

Info

Target: Searching
Days Since IPO: 135
Unit composition:
Each unit has an offering price of $10.00 and consists of one ordinary share and three-quarters of one redeemable warrant
Trust Size: 10000000.0M

🕵Stocktwit Mentions

Last10K posted at 2021-11-16T00:30:11Z

$CLAY just filed a 10-Q Quarterly Report with 35 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/clay/0001410578-21-000299.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=clay

cctranscripts posted at 2021-11-15T23:15:51Z

Chavant Capital Acquisition Corp. Just Filed Its Quarterly Report: Net Income (Loss) Pe... https://www.conferencecalltranscripts.com/summary/?id=10114322 $CLAY

risenhoover posted at 2021-11-15T22:25:03Z

$CLAY / Chavant Capital Acquisition files form 10-Q https://fintel.io/sf/us/clay?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2021-11-15T22:23:46Z

$CLAY 📜 SEC Form 10-Q filed by Chavant Capital Acquisition Corp. https://quantisnow.com/insight/2011370?s=s 45 seconds delayed.

Newsfilter posted at 2021-11-15T22:22:55Z

$CLAY Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/0761c26b77c0772e5c606fa4552288af

WarrenGShirley posted at 2021-11-08T16:12:53Z

$CLAY @ClayTrader25 @ClayTraderVideoAnalysis @CapitalPainz @clayvandiver @claybridge @ClayBro @Claydonkeydestroyer @LibertyTrades @chitownbull23 @clays26 @Flying_blind6 @gmanp68 Calling all Clay’s welcome 😆

jono86 posted at 2021-11-03T21:27:05Z

$CLAY 8th. Hunting cheap warrants. What's this.

WarrenGShirley posted at 2021-11-03T20:30:20Z

$CLAY searching Advanced manufacturing and advanced materials technology

WarrenGShirley posted at 2021-11-03T01:09:07Z

$CENQ $CLAQ $CLAY $IMAQ $MEOA Here are a couple of warrants I’ve been adding over the last week of trading. These are all 1:1 SPAC warrants that I’m accumulating under $.50 BNIX - Enterprise Software CENQ - Energy CLAQ - CleanTech or ClimateTech CLAY - Advanced manufacturing and advanced materials technology IMAQ - Media and Entertainment (Pelosi SPAC) (4:3 ratio not 1:1) MEOA - Minority-Owned Businesses REVE - Drive-to destination hotels, digital entertainment and gaming, and lodging tech

WarrenGShirley posted at 2021-10-29T16:48:46Z

$CLAY trying to pick up more warrants, but no sellers at $.51 for days 😢

WarrenGShirley posted at 2021-10-27T18:47:00Z

@Mossg135 let’s take $CLAY for example. CLAY common shares are trading at about $10. Warrants are a super long option to buy a common share at the strike price ($11.50 in this case and this is the typical strike price) Warrants typically don’t expire until 5 years after the IPO of the blank check company (CLAY). Warrants typically chase commons pretty tightly, for example if commons are worth $15, warrants should be worth $15-11.50= $3.50. Here is the disclaimer about warrants, if no merger happens and the SPAC has to give all their money back to the shareholders (which has happened 3 times over the 1000’s of SPACs) your warrants and rights go worthless. Warrants typically trade at lesser volume than commons and rights trade at less than warrants. If common shares close above $18 for 20 of a consecutive 30 days management will usually force warrant holders to redeem their warrants or sell them. This is good news because we buy at $.50 and they should be worth $6.50

WarrenGShirley posted at 2021-10-27T14:53:30Z

$CLAY finally picked up some warrants at $.51, y’all are free to spam 🤪

Mossg135 posted at 2021-10-27T13:06:04Z

$CLAY and 5th place goes to

EK2022 posted at 2021-10-27T01:12:20Z

$CLAY lol third? Joining the adventure

aaalex posted at 2021-10-26T23:08:31Z

$CLAY 2nd

WarrenGShirley posted at 2021-10-26T23:06:15Z

$CLAY first 🏆

Management

Our officers, directors and director nominees are as follows: Name Age Title Jiong Ma 57 Chief Executive Officer, President and Director André-Jacques Auberton-Hervé 59 Chairman of the Board of Directors Michael Lee 45 Chief Financial Officer Karen Kerr 52 Director nominee Bernhard Stapp 65 Director nominee Patrick J. Ennis 57 Director nominee Dr. Jiong Ma has been our Chief Executive Officer and President since March 2021. Since November 2020, Dr. Ma has been a Venture Partner at Braemar Energy Ventures (“Braemar”), an energy-focused venture capital firm. From 2008 to October 2020, Dr. Ma served as Senior Partner and a member of the investment committee at Braemar. While at Braemar, Dr. Ma has led investments in more than 15 companies involved in either resource efficiency, e-mobility, industrial digitalization, renewable energy, or deep tech, and has achieved multiple successful exits through M&A and IPO. During her career, she has served on the board of directors of more than 10 venture-backed companies, including Powervation (acquired by ROHM Semiconductor Ltd.), Convery Computer (acquired by Micron Technology, Inc.), mc10 (acquired by Medidata), and Carbonite Inc., which went public in 2011 and was subsequently acquired by OpenText (Nasdaq: OTEX) in 2019 for $1.45 billion. Dr. Ma currently serves on the board of Anavex Life Sciences Corp. (Nasdaq: AVXL) and as an advisory board member for each of Demeter Partners, a VC/PE fund dedicated to ecological and energy transformation in Europe, and National Renewable Energy Labs, a national laboratory of the U.S. Department of Energy which develops solutions to transform the generation, consumption, storage, and distribution of energy. From 2004 to 2008, Dr. Ma was an investment professional with the venture capital arm of 3i, a global private equity firm, where she led investments across multiple stages in technology and media, digital health, and cleantech. From 1997 to 2004, Dr. Ma held numerous senior positions at Lucent Technologies and Nortel Networks, where she was responsible for portfolio strategy, product development and research and development. In 2000, Dr. Ma co-founded Onetta Inc., an optical networking company, which was acquired by Bookham Technology in 2004. Dr. Ma holds a PhD in Electrical and Computer Engineering from the University of Colorado at Boulder, an MS in Electrical Engineering from Worchester Polytechnic Institute, and a BS in Physics and Electrical Engineering from Lanzhou University in China. Dr. Ma is also a Kauffman Fellow. Dr. Ma’s experiences in technology innovation, finance, and operations across multiple stages of business enable her to provide valuable leadership and expertise to our board of directors. Dr. André-Jacques Auberton-Hervé will serve as the Chairman of our board of directors following the completion of this offering. Dr. Auberton-Hervé serves as Chairman Emeritus of Soitec, a leader in Silicon-On-Insulator (SOI) technologies with a market capitalization of over $6 billion and a constituent company in the CAC Mid 60 Index, which he co-founded in 1992 out of a government laboratory and took public in Paris on the Euronext Stock Exchange in 1999. Serving for 23 years as Soitec’s President and Chief Executive Officer from July 1992 to January 2015, Dr. Auberton-Hervé was responsible for overseeing the company’s strategic, operational and financial activities that spanned across ten countries with five manufacturing facilities in Europe, Asia and the U.S. Dr. Auberton-Herve is the founder of 4A Consulting & Engineering, which provides strategic advice and consulting services with respect to renewable energy and digital innovation, and has served as its President and CEO since its founding in July 2015. In 2016, he became an operating partner of C4 Ventures, a leading European venture capital fund founded by Pascal Cagni (VP & GM EMEIA, Apple Inc., 2000-2012). In February 2018, he founded ATAJ, a company that he manages and that operates as advisor to Sofinnova Partners, a leading French venture capital fund, and its Sofinnova IT FPCI fund. Since January 2018, Dr. Auberton-Hervé has served as Chairman of the board of Bionik Laboratories Corp. In 2013, Dr. Auberton-Hervé was elected as Chairman of International Board of Directors of SEMI, the preeminent global industry association representing the electronics manufacturing industries. Dr. Auberton-Hervé is a recipient of numerous industry accolades, including the Audacity in Creativity Award from French President Jacques Chirac and the INSEAD Entrepreneurship Prize. Dr. Auberton-Hervé holds a doctorate degree with distinction in Physics from Ecole Centrale de Lyon. He is also a knight of the French Legion d’Honneur and the Ordre national du Mérite. 100 Dr. Auberton-Hervé’s entrepreneurial, technical and executive experience growing Soitec into a multibillion-dollar speciality electronic materials company, his stature as an international leader in advanced electronic materials, and his extensive experience and relationships make him highly qualified to serve on our board of directors to assist with our ultimate business combination transaction. Michael Lee has been our Chief Financial Officer since March 2021. Mr. Lee has over 22 years of experience in private equity and finance. He is currently the managing member of New Highland LLC, a finance consultancy for start-ups which he joined in 2013. Previously, from 2001 to 2013, Mr. Lee was a Director at Lincolnshire Management, a private equity firm, where he managed acquisitions and corporate divestitures and served in officer and board member roles of portfolio companies. Mr. Lee started his career at the merchant banking division of Wachovia Bank. He received a BA in Economics, magna cum laude, from Princeton University. Dr. Patrick Ennis will serve as a director following the completion of this offering. Dr. Patrick Ennis has over 30 years of experience as a scientist, engineer, businessman and venture capitalist. Since April 2019, Dr. Ennis has been a Venture Partner at Madrona Venture Group, a venture capital and private equity group focused on early-stage technology companies. Since April 2016, Dr. Ennis has served as a Director at Wipro Limited (NYSE: WIT), a global information technology, consulting and business process services company. From 2008 to March 2019, Dr. Ennis served as Global Head of Technology at Intellectual Ventures, a private equity firm specializing in invention, where he had responsibility for incubation, seed investments and technology commercialization, along with primary responsibility for investments in Asia. In January 2016, Dr. Ennis was the co-founding CTO of Xinova, a pioneer in global innovation market networks, and served as its CTO from inception to March 2019. From June 1998 to March 2008, Dr. Ennis was a Managing Director of ARCH Venture Partners, an early-stage venture firm, where he led seed and early-stage investments. He led the firm’s investments in Impinj (Nasdaq: PI) and Innovalight (acquired by DuPont). During his career, he has served on the boards of more than 20 venture-backed companies including Impinj, Innovalight, Kotura (acquired by Mellanox) and Artificial Muscle (acquired by Bayer Material Science). Prior to joining ARCH Venture Partners, Dr. Ennis held positions with Lucent Technologies, AT&T, and Bell Labs, where he led engineering projects for software development, speech recognition, network design and operations. Prior to Bell Labs, Dr. Ennis conducted research in Nuclear Physics at national and government laboratories in North America and Europe for seven years. Dr. Ennis is currently a Fellow at the Potomac Institute, a member of the University of Helsinki’s Commercialization Advisory Board, a member of the advisory board of Cybereason, a private global cybersecurity company, and an advisor to various companies in the defense industry. Dr. Ennis earned a Ph.D. and MS in Physics from Yale, an MBA from Wharton, and a BS in Math and Physics from the College of William & Mary where he was elected to Phi Beta Kappa. Dr. Ennis is a Kaufman Fellow. Dr. Ennis’s experience and track record in technology investing and early-stage business development brings substantial capabilities to our board of directors, with proprietary insight on leading-edge fields including machine learning, distributed computing and artificial intelligence. Dr. Karen Kerr will serve as a director following the completion of this offering. Dr. Kerr has over 25 years of experience in venture capital and technology investing. In May 2019, Dr. Kerr founded Exposition Ventures, a venture capital firm where she also serves as Managing Director. From April 2014 to April 2019, Dr. Kerr served as Executive Managing Director at GE Ventures, where she led investments in advanced manufacturing, supply chain technology, logistics, and enterprise software. Between 1996 and 2005, Dr. Kerr was a Managing Director at ARCH Venture Partners, where she helped grow assets under management to over $1 billion. Dr. Kerr has served as a director at Intellectual Ventures, and Senior Director of New Ventures and Alliances at the University of Southern California. Dr. Kerr started her career at Patricof & Co. and is a member of the Charter Class of Kauffman Fellows. Dr. Kerr is active on multiple boards, including the Kauffman Fellows, mHub, ORAU, the Clean Energy Trust and the Bryn Mawr College Board of Trustees. Dr. Kerr serves on the University of Chicago Physical Sciences Division and the Institute of Molecular Engineering Advisory Committees. Previously, Dr. Kerr served on the National Science Foundation’s Advisory Committee for the Small Business Innovative Research Program and on the National Institute for Standards and Technologies Visiting Committee on Advanced Technologies. Dr. Kerr earned a Ph.D. in Physical Chemistry from the University of Chicago and an A.B. in Chemistry from Bryn Mawr College. Dr. Kerr has been recognized as a Corporate Venture Capital Rising Star, a Crain’s Chicago Business Tech 50, one of LA’s Top Innovators, Crain’s Chicago Business 40 Under 40, and C200 Women Business Leaders. Dr. Kerr’s leadership roles and experience in both corporate ventures and institutional venture capital across numerous industries in advanced manufacturing, supply chain and logistics, and enterprise software add strong transactional experience and management capability to our board of directors. 101 Dr. Bernhard Stapp will serve as a director following the completion of this offering. Dr. Bernhard Stapp has served as President of CS-management GmbH, which provides consulting and advisory services to companies and investment firms with a focus on LED, OLED, photonics, cleantech and electronics materials, since November 2011. Between 2009 and 2011, Dr. Stapp served as Senior Vice President of Solid-State Lighting at OSRAM Licht AG, a global leader in optics and LED technology. Between 2001 and 2009, Dr. Stapp served in numerous roles at OSRAM Opto Semiconductors AG, including Chief Technology Officer and General Manager for LED and OLED components. Dr. Stapp began his career at Siemens AG where his roles included Head of Materials and Manufacturing, Group Leader of Functional Thin Films, and roles as Senior Scientist within the optical fiber, UV and ultrasound divisions. Dr. Stapp earned a Ph.D. in Metal Organics and a BS in Chemistry from the University Ulm in Germany. With his significant experience managing and advising various technology companies, particularly in the compound semiconductor and photonics space, we believe that Dr. Stapp will be a valuable addition to our board of directors. Number and Terms of Office of Officers and Directors Our board of directors will consist of five members and is divided into three classes with only one class of directors being appointed in each year, and with each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term. In accordance with Nasdaq rules, we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors, consisting of Dr. [ ], will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Dr. [ ] and Dr. [ ], will expire at the second annual general meeting. The term of office of the third class of directors, consisting of Dr. [ ], will expire at the third annual general meeting. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association. Director Independence Nasdaq’s listing standards require that a majority of our board of directors be independent within one year of our initial public offering. Our board of directors has determined that Dr. Kerr, Dr. Ennis and Dr. Stapp are “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. We will pay New Highland, LLC, of which our Chief Financial Officer is the managing member, for consulting services and the preparation of our financial statements for the period commencing March 1, 2021 until the consummation of our initial business combination as follows: (i) $10,000 for the preparation of the financial statements for the registration statement of which this prospectus forms a part; (ii) $5,000 for the preparation of the financial statements required to be filed in our Current Report on Form 8-K following the completion of this offering; (iii) $5,000 for the preparation of financial statements for each of our Quarterly Reports on Form 10-Q; and (iv) $10,000 for the preparation of financial statements for each of our Annual Reports on Form 10-K. Our sponsor, executive officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that are made to our sponsor, executive officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. 102 We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will have two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 under the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Dr. Kerr, Dr. Ennis and Dr. Stapp will serve as members of our audit committee. Under Nasdaq’s listing standards and applicable SEC rules, we are required to have three members of the audit committee, all of whom must be independent, subject to the exception described below. Dr. Kerr, Dr. Ennis and Dr. Stapp are independent. Dr. Kerr will serve as the chairman of the audit committee. Each member of the audit committee is financially literate and our board of directors has determined that Dr. Kerr qualifies as an “audit committee financial expert” as defined in applicable SEC rules. The audit committee is responsible for: •meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; •monitoring the independence of the independent registered public accounting firm; •verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; •inquiring and discussing with management our compliance with applicable laws and regulations; •pre-approving all audit services and permitted non-audit services to be performed by our independent register

Holder Stats

1 0
% of Shares Held by All Insider 16.56%
% of Shares Held by Institutions 1.53%
% of Float Held by Institutions 1.84%
Number of Institutions Holding Shares 1

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-17 Altium Capital Management LP 200,000 $1,970,000 0.4% 0 1.942%
2021-11-16 Schonfeld Strategic Advisors LLC 15,000 $150,000 0.0% 0 0.146%
2021-11-16 Oaktree Capital Management LP 150,000 $1,480,000 0.0% 0 1.456%
2021-11-16 Whitebox Advisors LLC 250,000 $2,460,000 0.1% 0 2.427%
2021-11-16 Warberg Asset Management LLC 10,000 $99,000 0.0% 0 0.097%
2021-11-16 Beryl Capital Management LLC 50,000 $490,000 0.0% 0 0.485%
2021-11-16 CNH Partners LLC 197,128 $1,950,000 0.1% 0 1.914%
2021-11-16 CVI Holdings LLC 150,000 $1,480,000 0.1% 0 1.456%
2021-11-15 Ancora Advisors LLC 5,900 $58,000 0.0% 0 0.057%
2021-11-15 Polar Asset Management Partners Inc. 800,000 $7,880,000 0.1% 0 7.767%
2021-11-15 Rivernorth Capital Management LLC 11,172 $110,000 0.0% 0 0.108%
2021-11-15 Berkley W R Corp 384,873 $3,790,000 0.3% 0 3.737%
2021-11-12 Periscope Capital Inc. 370,093 $3,650,000 0.1% 0 3.593%
2021-11-12 Arena Capital Advisors LLC CA 500,000 $4,930,000 0.4% 0 4.854%
2021-11-12 Weiss Asset Management LP 428,988 $4,230,000 0.1% 0 4.165%
2021-11-12 Wolverine Asset Management LLC 188,500 $1,860,000 0.0% 0 1.830%
2021-11-12 Cohanzick Management LLC 242,965 $2,390,000 0.6% 0 2.359%
2021-11-10 Goldman Sachs Group Inc. 65,580 $650,000 0.0% 0 0.637%
2021-11-09 ATW Spac Management LLC 50,000 $490,000 0.1% 0 0.485%
2021-11-09 Basso Capital Management L.P. 199,896 $1,970,000 0.2% 0 1.941%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2021-11-15 https://www.sec.gov/Archives/edgar/data/1855467/000141057821000299/clay-20210930x10q.htm
4 OWNERSHIP DOCUMENT 2021-09-21 https://www.sec.gov/Archives/edgar/data/1855467/000110465921118025/xslF345X03/tm2128151-2_4.xml
4 OWNERSHIP DOCUMENT 2021-09-21 https://www.sec.gov/Archives/edgar/data/1855467/000110465921118023/xslF345X03/tm2128151-1_4.xml
10-Q FORM 10-Q 2021-09-02 https://www.sec.gov/Archives/edgar/data/1855467/000110465921112469/clay-20210630x10q.htm
8-K 8-K 2021-08-03 https://www.sec.gov/Archives/edgar/data/1855467/000110465921099554/tm2123840d1_8k.htm
8-K FORM 8-K 2021-07-28 https://www.sec.gov/Archives/edgar/data/1855467/000110465921096982/tm2112269d10_8k.htm
SC 13G SCHEDULE 13G 2021-07-26 https://www.sec.gov/Archives/edgar/data/1855467/000110465921095751/tm2123187d1_sc13g.htm
3 OWNERSHIP DOCUMENT 2021-07-23 https://www.sec.gov/Archives/edgar/data/1855467/000110465921095331/xslF345X02/tm2122362-5_3seq1.xml
8-K FORM 8-K 2021-07-23 https://www.sec.gov/Archives/edgar/data/1855467/000110465921095311/tm2112269d9_8k.htm
3 OWNERSHIP DOCUMENT 2021-07-22 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094909/xslF345X02/tm2122362-7_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-07-21 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094530/xslF345X02/tm2122362-6_3seq1.xml
424B4 424B4 2021-07-21 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094497/tm2112269-6_424b4.htm
3 OWNERSHIP DOCUMENT 2021-07-20 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094078/xslF345X02/tm2122362-4_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-07-20 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094076/xslF345X02/tm2122362-3_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-07-20 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094059/xslF345X02/tm2122362d2_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-07-20 https://www.sec.gov/Archives/edgar/data/1855467/000110465921094047/xslF345X02/tm2122362d1_3seq1.xml
EFFECT 2021-07-19 https://www.sec.gov/Archives/edgar/data/1855467/999999999521002828/xslEFFECTX01/primary_doc.xml
CERT 2021-07-15 https://www.sec.gov/Archives/edgar/data/1855467/000135445721000806/8A_cert_CLAY.pdf
8-A12B FORM 8-A 2021-07-15 https://www.sec.gov/Archives/edgar/data/1855467/000110465921092537/tm2122334d1_8a12b.htm
S-1/A S-1/A 2021-07-14 https://www.sec.gov/Archives/edgar/data/1855467/000110465921092145/tm2112269d4_s1a.htm
S-1/A S-1/A 2021-07-09 https://www.sec.gov/Archives/edgar/data/1855467/000110465921090407/tm2112269d3_s1a.htm
S-1 FORM S-1 2021-06-25 https://www.sec.gov/Archives/edgar/data/1855467/000110465921085853/tm2112269d2_s1.htm
DRS 2021-04-09 https://www.sec.gov/Archives/edgar/data/1855467/000110465921048499/filename1.htm